ArticleTheranostics2021
A blood circulation-prolonging peptide anchored biomimetic phage-platelet hybrid nanoparticle system for prolonged blood circulation and optimized anti-bacterial performance.
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Research progress on nanomaterials in promoting phage function and application.Applied and environmental microbiology · 2026Review
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- Article
- Engineered phage-silver nanoparticle complexes as a new tool for targeted therapies.Scientific reports · 2025Article
- Natural, Engineered, and Hybrid Platelet Membrane-Based Nanotherapeutics for Inflammatory Diseases.International journal of nanomedicine · 2025Review
- Phage-specific antibodies: are they a hurdle for the success of phage therapy?Essays in biochemistry · 2024Review
- Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.Journal of nanobiotechnology · 2024Review
- Review
- Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy.Viruses · 2023Review
- Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy.Materials today. Bio · 2023Review
- Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection.Frontiers in microbiology · 2023Review
- Membrane-camouflaged biomimetic nanoparticles as potential immunomodulatory solutions for sepsis: An overview.Frontiers in bioengineering and biotechnology · 2023Review
- Biomimetic Nanomaterials: Diversity, Technology, and Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Advances in the Application of Nanomaterials as Treatments for Bacterial Infectious Diseases.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy holds great promise for resolving the ever-worsening crisis of antibiotic resistance, but it also faces many challenges. One of the issues hampering phage therapy is the short blood residence time of bacteriophages. We have previously identified, through
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.